EG-007

DRUG2 trials

Sponsors

Evergreen Therapeutics, Inc.

Conditions

Advanced Endometrial Cancer

Phase 2

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Not yet recruitingNCT05106127

Evergreen Therapeutics, Inc.Advanced Endometrial Cancer

Start: 2026-08-31End: 2027-03-31Target: 28Updated: 2025-12-08

Phase 3

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Not yet recruitingNCT05077215

Evergreen Therapeutics, Inc.Advanced Endometrial Cancer

Start: 2026-12-31End: 2027-12-31Target: 450Updated: 2025-12-08